nach oben

Supportive Care in Cancer

Erschienen in:

01.04.2008 | Original Article

Cancer-associated hypercalcemia treated with intravenous diphosphonates: a survival and prognostic factor analysis

verfasst von: Nicolas Penel, Sylvain Dewas, Philippe Doutrelant, Stéphanie Clisant, Yazdan Yazdanpanah, Antoine Adenis

Erschienen in: Supportive Care in Cancer | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Abstract

Background

Cancer-associated hypercalcemia (CAH) is the most frequent metabolic disorder in cancer patients. We retrospectively reviewed the outcome and prognostic factors for patients with CAH being treated with standard intravenous disphosphonates.

Materials and methods

Two hundred sixty patients were reviewed. Overall survival and prognostic factors were analyzed. Relative risks (RR) for early death (within 60 days) were assessed (Fischer exact test and logistic regression model).

Results

Median survival was 64 days (range, 12–1,955+). Multivariate analysis identified the following factors as poor survival predictors: serum corrected calcium >2.83 mmol/l [hazard ratio (HR) = HR 2.21], albuminemia <35.5 (HR 2.41), squamous cell carcinoma (HR 2.64), bone metastasis (HR 1.44), and liver metastasis (HR 2..22). One hundred twenty-one patients died within 60 days. For those patients, the logistic regression model identified four independent predicting factors for early death: calcemia >2.83 mmol/l (RR 5.07), hypoalbuminemia (RR 7.42), liver metastasis (RR 4.34), and squamous cell carcinomas (RR 2.21).

Discussion

Despite intravenous diphosphonate, CAH is still associated with poor outcome. Simple bedside parameters may estimate the risk of early deaths.

Besarb A, Caro JF (1978) Mechanisms of hypercalcemia in malignancy. Cancer 41:2276–2285CrossRef

Brada M, Rowley M, Grant DJ, Ashley S, Powles TJ (1990) Hypercalcemia in patients with disseminated breast cancer. Acta Oncol 29:577–580PubMedCrossRef

Body JJ, Borkowski A, Cleeren A et al (1986) Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate. J Clin Oncol 4:1177–1183PubMed

Nussbaum SR, Younger J, Vandepol CJ et al (1993) Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med 95:297–304PubMedCrossRef

Rogers MJ, Gordon S, Benford HL et al (2000) Cellular and molecular mechanisms of action of biphosphonates. Cancer 88:2961–2978PubMedCrossRef

Major P, Lhortolary A, Hon J et al (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy a pooled analysis of two-randomized controlled clinical trials. J Clin Oncol 19:558–567PubMed

Monno S, Nagata A, Furuta S (1987) Hypercalcemia of cancer in the aerodigestive tract. J Clin Gastroenterol 9:78–82PubMedCrossRef

Ralston SH, Gallacher SJ, Patel U, Campbell J, Boyle IT (1990) Cancer-associated hypercalcemia morbidity and mortality. Clinical experience in 126 treated patients. Ann Intern Med 112:499–504PubMed

Cvitkovic F, Armand JP, Tubiana-Hulin M, Rossi JF, Warrell RP Jr (2006) Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia. Cancer J 12:47–53PubMedCrossRef

10.

Kristensen B, Ejlersten B, Mouridsen HT, Loft H (1998) Survival in breast cancer patients after the first episode of hypercalcemia. J Intern Med 244:189–198PubMedCrossRef

11.

Payne RB, Carver ME, Morgan DB (1979) Interpretation of serum total calcium effects of adjustment for albumin concentration on frequency of abnormal values and on detection of change in the individual. J Clin Pathol 32:56–60PubMedCrossRef

12.

Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRef

13.

Mantel N (1966) Estimation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163–170PubMed

14.

Cox D (1972) Regression models and life tables (with discussion). J R Stat Soc B 34:187–220

15.

Chasan SA, Pothel LR, Huben RP (1989) Management and prognostic significance of hypercalcemia in renal cell carcinomas. J Urology 33:167–170CrossRef

16.

Degardin M, N’Guyen M, Beaurin D et al (1995) Hypercalcémie et carcinomes épidermoides des voies aéro-digestives supérieures. Incidence et pronostic. Bull Cancer 82:975–980PubMed

17.

Fahn HJ, Lee YH, Chen MT, Huang JK, Chen KK, Chang LS (1991) The incidence and prognostic significance of humoral hypercalcemia in renal cell carcinoma. J Urol 145:248–250PubMed

18.

Penel N Berthon C, Everard F et al (2005) Prognosis of hypercalcemia in aerodigestive tract cancers Study of 136 recent cases. Oral Oncology 41:884–889CrossRef

19.

Wysolmerski JJ, Broadus AE (1994) Hypercalcemia of malignancy: the central role of parathyroid hormone related protein. Ann Rev Med 45:189–200PubMedCrossRef

20.

Skrabanek P, Mc Partlin J, Powell D (1980) Tumor hypercalcemia and “ectopic” hyperparathyroidism”. Medicine 59:262–282PubMedCrossRef

21.

Wimalawansa SJ (1994) Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated. with diphosphonate. Cancer 73:2223–2230PubMedCrossRef

22.

Walls J, Ratcliffe WA, Howell A, Bundred NJ (1994) Response to intravenous biphosphonate therapy in hypercalcemic patients without bone metastases: the role of parathyroid hormone-related protein. Br J Cancer 70:169–172PubMed

23.

Gurney H, Grill V, Martin TJ (1993) Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcemia. Lancet 341:1611–1613PubMedCrossRef

24.

De Wits S, Cleton FJ (1994) Hypercalcemia in patients with breast cancer: a survival study. J Cancer Res Clin Oncol 120:610–614CrossRef

25.

Truong NU, deB Edwardes MD, Papavasiliou V, Goltzman D, Kremer R (2003) Parathyroid hormone-related peptide and survival with cancer and hypercalcemia. Am J Med 115:115–121PubMedCrossRef

26.

Augustson BM, Begum G, Dunn JA et al (2005) Early mortality after diagnosis of multiple myeloma analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 - Medical Research Council Adult Leukemia Working Party. J Clin Oncol 23:9219–9226PubMedCrossRef

27.

Ling PJ, A’Hern RP, Hardy JR (1995) Analysis of survival following treatment of tumour-induced hypercalcemia with intravenous pamidronate (APD). Br J Cancer 72:206–209PubMed

Titel: Cancer-associated hypercalcemia treated with intravenous diphosphonates: a survival and prognostic factor analysis
verfasst von: Nicolas Penel
Sylvain Dewas
Philippe Doutrelant
Stéphanie Clisant
Yazdan Yazdanpanah
Antoine Adenis
Publikationsdatum: 01.04.2008
Verlag: Springer-Verlag
Erschienen in: Supportive Care in Cancer / Ausgabe 4/2008
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-007-0322-z

Springer Medizin

Cancer-associated hypercalcemia treated with intravenous diphosphonates: a survival and prognostic factor analysis